Intech Investment Management LLC Sells 4,659 Shares of West Pharmaceutical Services, Inc. (NYSE:WST)

Intech Investment Management LLC trimmed its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 22.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,361 shares of the medical instruments supplier’s stock after selling 4,659 shares during the period. Intech Investment Management LLC’s holdings in West Pharmaceutical Services were worth $6,474,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Evoke Wealth LLC bought a new stake in shares of West Pharmaceutical Services during the 4th quarter valued at $7,770,000. Sumitomo Mitsui Trust Holdings Inc. increased its holdings in West Pharmaceutical Services by 1.5% in the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 191,469 shares of the medical instruments supplier’s stock valued at $75,766,000 after acquiring an additional 2,759 shares during the last quarter. International Assets Investment Management LLC increased its holdings in West Pharmaceutical Services by 13,230.0% in the 4th quarter. International Assets Investment Management LLC now owns 18,662 shares of the medical instruments supplier’s stock valued at $6,571,000 after acquiring an additional 18,522 shares during the last quarter. Vanguard Group Inc. increased its holdings in West Pharmaceutical Services by 1.2% in the 4th quarter. Vanguard Group Inc. now owns 9,002,632 shares of the medical instruments supplier’s stock valued at $3,170,007,000 after acquiring an additional 104,740 shares during the last quarter. Finally, Hsbc Holdings PLC increased its holdings in West Pharmaceutical Services by 39.8% in the 4th quarter. Hsbc Holdings PLC now owns 138,468 shares of the medical instruments supplier’s stock valued at $48,750,000 after acquiring an additional 39,392 shares during the last quarter. 93.90% of the stock is currently owned by institutional investors.

West Pharmaceutical Services Price Performance

NYSE WST traded up $1.58 on Friday, reaching $317.92. The company had a trading volume of 554,640 shares, compared to its average volume of 486,570. The company has a quick ratio of 1.95, a current ratio of 2.61 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $23.16 billion, a PE ratio of 41.94, a price-to-earnings-growth ratio of 5.61 and a beta of 1.00. The firm’s 50 day moving average price is $329.16 and its 200 day moving average price is $357.18. West Pharmaceutical Services, Inc. has a 12 month low of $310.00 and a 12 month high of $415.73.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings results on Thursday, April 25th. The medical instruments supplier reported $1.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.29 by $0.27. West Pharmaceutical Services had a net margin of 19.42% and a return on equity of 20.57%. The company had revenue of $695.40 million for the quarter, compared to the consensus estimate of $670.62 million. During the same period in the previous year, the firm posted $1.98 EPS. West Pharmaceutical Services’s revenue for the quarter was down 3.0% compared to the same quarter last year. As a group, equities analysts predict that West Pharmaceutical Services, Inc. will post 7.76 earnings per share for the current year.

West Pharmaceutical Services Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, August 7th. Stockholders of record on Wednesday, July 31st will be issued a $0.20 dividend. The ex-dividend date is Wednesday, July 31st. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.25%. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 10.55%.

Insider Transactions at West Pharmaceutical Services

In related news, SVP Silji Abraham sold 1,800 shares of West Pharmaceutical Services stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $330.78, for a total transaction of $595,404.00. Following the completion of the transaction, the senior vice president now directly owns 2,860 shares of the company’s stock, valued at approximately $946,030.80. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In related news, SVP Silji Abraham sold 1,800 shares of West Pharmaceutical Services stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $330.78, for a total transaction of $595,404.00. Following the completion of the transaction, the senior vice president now directly owns 2,860 shares of the company’s stock, valued at approximately $946,030.80. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Eric Mark Green sold 66,000 shares of West Pharmaceutical Services stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $366.65, for a total transaction of $24,198,900.00. Following the transaction, the chief executive officer now directly owns 152,908 shares of the company’s stock, valued at $56,063,718.20. The disclosure for this sale can be found here. Insiders own 0.53% of the company’s stock.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.